NCT00003471 - Antineoplaston Therapy in Treating Patients With Low-Grade Astrocytoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 1996

Primary Completion Date

July 31, 2003

Study Completion Date

July 31, 2003

Conditions

Low-Grade Astrocytoma, Nos

Interventions

DRUG

Antineoplaston therapy (Atengenal + Astugenal)

"Adults with a recurrent/progressive low grade astrocytoma will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."

Trial Locations (1)

77055-6330

Burzynski Clinic, Houston